Pharmaceutical Technology

JUNE 6, 2023

The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Buy the model here. over FY2021. in FY2021.

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

Bioengineer

JANUARY 16, 2024

Often, the loss of T790M is associated with the development of alternative competitive resistance mechanisms. Importantly, a triple mutant scenario with EGFR L858R/T790M/C797S or EGFRexon19del/T790M/C797S genotype may occur in patients with T790-positive NSCLC receiving osimertinib in second or later lines. months vs. 15.2

Genome 119

Genome Genomics Protein In-Vitro 119

XTalks

JANUARY 22, 2021

Taiwan-based health and biotech company MedFluid has developed a rapid automated bacterial identification screening tool that can also tailor antibiotic treatments to an infection. It identifies bacteria using both genotypic and phenotypic assessments within 1.5

Bacteria 52

Bacteria In-Vitro Genotype Marketing 52

The Pharma Data

MARCH 16, 2022

It’s critical to quickly and accurately identify variants to inform ongoing research – including the ongoing development of therapeutics and vaccines. Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, 3 and Delta.

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

The Pharma Data

DECEMBER 9, 2020

Liebisch , Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia. It will if the following five companies, which all launched this year with Series A financing, have anything to say about it. . Vigil Neuroscience.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

DECEMBER 9, 2020

Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

Drug Discovery World

FEBRUARY 9, 2024

DDW recently hosted a webinar ‘Discover how iPSC derived cells can be used to support the development of drug and gene therapies’, supported by DefiniGEN. Chris explained that DefiniGEN is a liver cell company focussed on hepatocytes, particularly supporting the drug development industry in producing liver therapies.

Gene Therapy 52

Gene Therapy Gene Development Drugs 52